Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review
Open Access
- 26 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1402837
Abstract
Lymphocyte activation gene 3 (LAG-3), also known as CD223, is an emerging immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in clinical trials and the combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) have been approved for treating - unresectable or metastatic melanoma. Despite the encouraging clinical potential of LAG-3, the physiological function and mechanism of action in tumors are still not well understood. In this review, we systematically summarized the structure of LAG-3, ligands of LAG-3, cell-specific functions and signaling of LAG-3, and the current status of LAG-3 inhibitors under development.Keywords
This publication has 107 references indexed in Scilit:
- Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture modelsGastric Cancer, 2021
- 1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)Annals of Oncology, 2020
- 1032P Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumour entitiesAnnals of Oncology, 2020
- Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expressionCancer Medicine, 2020
- Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastomaInternational Journal of Cancer, 2018
- NK/DC crosstalk in immunosurveillance: A broken relationship caused by WASP‐deficiencyEuropean Journal of Immunology, 2014
- Wiskott–Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunityEuropean Journal of Immunology, 2013
- LAG-3 in Cancer Immunotherapy2010
- Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivoEuropean Journal of Immunology, 2002
- Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytesEuropean Journal of Immunology, 1994